AllRock Bio, founded by former CinCor Pharma executives, emerged from stealth with a $65 million Series A to advance a small molecule pan-ROCK inhibitor licensed from Sanofi. The drug candidate targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease. Leveraging expertise that led to CinCor’s acquisition by AstraZeneca, AllRock is positioning to address severe lung conditions with oral therapeutics.